Clinical success of in utero transplantation (IUT) using allogeneic hematopoietic stem cells (HSCs) has been limited to fetuses that lack an immune response to allogeneic cells due to severe immunological defects, and where transplanted genetically normal cells have a proliferative or survival advantage. Amniotic fluid (AF) is an autologous source of stem cells with hematopoietic potential that could be used to treat congenital blood disorders. We compared the ability of congenic and allogeneic mouse AF stem cells (AFSC) to engraft the hematopoietic system of time-mated C57BL/6J mice (E13.5). At 4 and 16 weeks of age, multilineage donor engraftment was higher in congenic versus allogeneic animals. In vitro mixed lymphocyte reaction confirmed an immune response in the allogeneic group with higher CD4 and CD8 cell counts and increased proliferation of stimulated lymphocytes. IUT with congenic cells resulted in 100% of donor animals having chimerism of around 8% and successful hematopoietic long-term engraftment in immune-competent mice when compared with IUT with allogeneic cells. AFSCs may be useful for autologous cell/gene therapy approaches in fetuses diagnosed with congenital hematopoietic disorders.
Get full access to this article
View all access options for this article.
References
1.
TibladE and WestgrenM. (2008). Fetal stem-cell transplantation. Best Pract Res Clin Obstet Gynaecol, 22:189–201.
2.
GötherströmC, WestgrenM, ShawSWS, AströmE, BiswasA, ByersPH, MattarCNZ, GrahamGE, TaslimiJ, et al. (2014). Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience. Stem Cells Transl Med, 3:255–264.
3.
GuillotPV, AbassO, BassettJHD, ShefelbineSJ, Bou-GhariosG, ChanJ, KurataH, WilliamsGR, PolakJ and FiskNM. (2008). Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood, 111:1717–1725.
4.
WestgrenM, RingdenO, Eik-NesS, EkS, AnvretM, BrubakkAM, BuiTH, GiambonaA, KiserudT, et al. (1996). Lack of evidence of permanent engraftment after in utero fetal stem cell transplantation in congenital hemoglobinopathies. Transplantation, 61:1176–1179.
5.
PeranteauWH, EndoM, AdibeOO, MerchantA, ZoltickPW and FlakeAW. (2006). CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation. Blood, 108:4268–4274.
6.
PeranteauWH, EndoM, AdibeOO and FlakeAW. (2006). Evidence for an immune barrier after in utero hematopoietic-cell transplantation. Blood, 109:1331–1333.
7.
NijagalA, WegorzewskaM, LeT, TangQ and MacKenzieTC. (2011). The maternal immune response inhibits the success of in utero hematopoietic cell transplantation. Chimerism, 2:55–57.
8.
MerianosDJ, TibladE, SantoreMT, TodorowCA, LajeP, EndoM, ZoltickPW and FlakeAW. (2009). Maternal alloantibodies induce a postnatal immune response that limits engraftment following in utero hematopoietic cell transplantation in mice. J Clin Invest, 121:582–592.
9.
PeranteauWH, HayashiS, AbdulmalikO, ChenQ, MerchantA, AsakuraT and FlakeAW. (2015). Correction of murine hemoglobinopathies by prenatal tolerance induction and postnatal nonmyeloablative allogeneic BM transplants. Blood, 126:1245–1254.
10.
PrusaA-R, MartonE, RosnerM, BernaschekG and HengstschlägerM. (2003). Oct-4-expressing cells in human amniotic fluid: a new source for stem cell research?. Hum Reprod, 18:1489–1493.
11.
FauzaD. (2004). Amniotic fluid and placental stem cells. Best Pract Res Clin Obstet Gynaecol, 18:877–891.
12.
De CoppiP, CallegariA, ChiavegatoA, GasparottoL, PiccoliM, TaianiJ, PozzobonM, BoldrinL, OkabeM, et al. (2007). Amniotic fluid and bone marrow derived mesenchymal stem cells can be converted to smooth muscle cells in the cryo-injured rat bladder and prevent compensatory hypertrophy of surviving smooth muscle cells. J Urol, 177:369–376.
13.
DitadiA, de CoppiP, PiconeO, GautreauL, SmatiR, SixE, BonhommeD, EzineS, FrydmanR, Cavazzana-CalvoM and André-SchmutzI. (2009). Human and murine amniotic fluid c-Kit+Lin- cells display hematopoietic activity. Blood, 113:3953–3960.
14.
PiccoliM, FranzinC, BertinE, UrbaniL, BlaauwB, RepeleA, TaschinE, CenedeseA, ZanonGGF, et al. (2012). Amniotic fluid stem cells restore the muscle cell niche in a HSA-Cre, SmnF7/F7 mouse model. Stem Cells, 30:1675–1684.
15.
De CoppiP, BartschG, SiddiquiMM, XuT, SantosCC, PerinL, MostoslavskyG, SerreAC, SnyderEY, et al. (2007). Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol, 25:100–106.
16.
LoukogeorgakisSP and De CoppiP. (2016). Stem cells from amniotic fluid - Potential for regenerative medicine. Best Pract Res Clin Obstet Gynaecol, 31:45–57.
17.
GrisafiD, PiccoliM, PozzobonM, DitadiA, ZaramellaP, ChiandettiL, ZanonGF, AtalaA, ZacchelloF, et al. (2008). High transduction efficiency of human amniotic fluid stem cells mediated by adenovirus vectors. Stem Cells Dev, 17:953–962.
18.
ShawSWS, DavidAL and De CoppiP. (2011). Clinical applications of prenatal and postnatal therapy using stem cells retrieved from amniotic fluid. Curr Opin Obstet Gynecol, 23:109–116.
19.
RamachandraDL, ShawSSW, ShangarisP, LoukogeorgakisS, GuillotPV, De CoppiP and DavidAL. (2014). In utero therapy for congenital disorders using amniotic fluid stem cells. Front Pharmacol, 5:270.
20.
ShawSWSWS, BlundellMPMP, PipinoC, ShangarisP, MaghsoudlouP, RamachandraDLDL, GeorgiadesF, BoydM, ThrasherAJAJ, et al. (2015). Sheep CD34+ amniotic fluid cells have hematopoietic potential and engraft after autologous in utero transplantation. Stem Cells, 33:122–132.
21.
ShawSWS, BolliniS, NaderKA, GastaldelloA, MehtaV, FilppiE, CananziM, GasparHB, QasimW, De CoppiP and DavidAL. (2016). Autologous transplantation of amniotic fluid-derived mesenchymal stem cells into sheep fetuses. Cell Transplant, 25:615.
22.
VeibyOP, LoCastroS, BhatnagarP and OlsenWM. (1996). Inhibition of enriched stem cells in vivo and in vitro by the hemoregulatory peptide SK&F108636. Stem Cells, 14:215–224.
23.
WegorzewskaM, NijagalA, WongCM, LeT, LescanoN, TangQ and MacKenzieTC. (2014). Fetal intervention increases maternal T cell awareness of the foreign conceptus and can lead to immune-mediated fetal demise. J Immunol, 192:1938–1945.
24.
NijagalA, FlakeAW and MacKenzieTC. (2012). In utero hematopoietic cell transplantation for the treatment of congenital anomalies. Clin Perinatol, 39:301–310.
25.
MoldJE, MichaëlssonJ, BurtTD, MuenchMO, BeckermanKP, BuschMP, LeeT, NixonDF, McCuneJM, KarenP and JosephM. (2008). Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science, 322:1562–1565.
26.
SinghKP, GerardHC, HudsonAP, ReddyTR and BorosDL. (2005). Retroviral Foxp3 gene transfer ameliorates liver granuloma pathology in Schistosoma mansoni infected mice. Immunology, 114:410–417.
27.
SteinmanRA. (2002). Cell cycle regulators and hematopoiesis. Oncogene, 21:3403–3413.
28.
SrivastavaAS, KaushalS, MishraR, a LaneT and CarrierE. (2006). Dexamethasone facilitates erythropoiesis in murine embryonic stem cells differentiating into hematopoietic cells in vitro. Biochem Biophys Res Commun, 346:508–516.
29.
FisherJE, LillegardJB, McKenzieTJ, RodysillBR, WettsteinPJ and NybergSL. (2013). In utero transplanted human hepatocytes allows for postnatal engraftment of human hepatocytesin pigs. Liver Transpl, 19:328–335.
30.
LoukogeorgakisSP and FlakeAW. (2014). In utero stem cell and gene therapy: current status and future perspectives. Eur J Pediatr Surg, 24:237–245.
31.
HayashiS, AbdulmalikO, PeranteauWH, AshizukaS, CampagnoliC, ChenQ, HoriuchiK, AsakuraT and FlakeAW. (2003). Mixed chimerism following in utero hematopoietic stem cell transplantation in murine models of hemoglobinopathy. Exp Hematol, 31:176–184.
32.
DerderianSC, TogarratiPP, KingC, MoradiPW, ReynaudD, CzechowiczA, WeissmanIL and MacKenzieTC. (2014). In utero depletion of fetal hematopoietic stem cells improves engraftment after neonatal transplantation in mice. Blood, 124:973–980.
33.
NijagalA, DerderianC, LeT, JarvisE, NguyenL, TangQ and MackenzieTC. (2013). Direct and indirect antigen presentation lead to deletion of donor-specific T cells after in utero hematopoietic cell transplantation in mice. Blood. 4595–4602.
34.
BilateAM and LafailleJJ. (2012). Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol, 30:733–758.
35.
SpencePJ and GreenEA. (2008). Foxp3+ regulatory T cells promiscuously accept thymic signals critical for their development. Proc Natl Acad Sci U S A, 105:973–978.
36.
BurtTD. (2013). Fetal regulatory T cells and peripheral immune tolerance in utero: implications for development and disease. Am J Reprod Immunol, 69:346–358.
37.
van der NetJB, BushellA, WoodKJ and HardenPN. (2016). Regulatory T cells: first steps of clinical application in solid organ transplantation. Transpl Int, 29:3–11.
38.
Velásquez-LoperaMM, EatonVL, LerretNM, CorreaLA, DeCresceRP, GarcíaLF and JaramilloA. (2008). Induction of transplantation tolerance by allogeneic donor-derived CD4+CD25+Foxp3+ regulatory T cells. Transpl Immunol, 19:127–135.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
